Shangguan Jian, Huang Xinyi, Liu Xu, Zhang Zengfu, Zhang Xiaodong, Yu Jinming, Chen Dawei
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Front Oncol. 2023 May 2;13:1195499. doi: 10.3389/fonc.2023.1195499. eCollection 2023.
The utilization of the Gustave Roussy Immune Score (GRIm-Score) in patient selection for immunotherapy was initially reported. The objective of this retrospective study is to assess the potential of the GRIm-Score, a novel prognostic score based on nutritional and inflammatory markers, as a prognostic predictor in patients with small cell lung cancer (SCLC) undergoing immunotherapy.
This retrospective study conducted at a single center included 159 patients with SCLC who received immunotherapy. The objective of the study was to investigate potential differences in overall survival (OS) and progression-free survival (PFS) among patients stratified by their GRIm-Score, utilizing the Kaplan-Meier survival analysis and the log-rank test. The final independent prognostic factors were identified through both propensity score matching (PSM) analysis and multivariable Cox proportional hazards regression analysis.
Our analysis of the 159 patients revealed that there was a significant decrease in both OS and PFS with each increase in the GRIm-Score group, displaying a stepwise pattern. Moreover, even after conducting PSM analysis, the significant associations between the modified three-category risk scale-based GRIm-Score and survival outcomes remained significant. Both the total cohort and PSM cohort were subjected to multivariable analysis, which demonstrated that the three-category risk assessment-based GRIm-Score was a valuable predictor of both OS and PFS.
In addition, the GRIm-Score may serve as a valuable and non-invasive prognostic predictor for SCLC patients undergoing PD1/PD-L1 immunotherapy.
最初报道了古斯塔夫·鲁西免疫评分（GRIm-Score）在免疫治疗患者选择中的应用。这项回顾性研究的目的是评估GRIm-Score（一种基于营养和炎症标志物的新型预后评分）作为接受免疫治疗的小细胞肺癌（SCLC）患者预后预测指标的潜力。
这项在单一中心进行的回顾性研究纳入了159例接受免疫治疗的SCLC患者。该研究的目的是利用Kaplan-Meier生存分析和对数秩检验，调查根据GRIm-Score分层的患者在总生存期（OS）和无进展生存期（PFS）方面的潜在差异。通过倾向评分匹配（PSM）分析和多变量Cox比例风险回归分析确定最终的独立预后因素。
我们对159例患者的分析显示，随着GRIm-Score组别的每一次增加，OS和PFS均显著降低，呈现出逐步变化的模式。此外，即使在进行PSM分析后，基于改良的三类风险量表的GRIm-Score与生存结果之间的显著关联仍然显著。对整个队列和PSM队列都进行了多变量分析，结果表明基于三类风险评估的GRIm-Score是OS和PFS的有价值预测指标。
此外，GRIm-Score可能是接受PD1/PD-L1免疫治疗的SCLC患者有价值的非侵入性预后预测指标。
